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The objective of this study is to identify genetic factors associated with chronic kidney
disease (CKD) and related cardiometabolic phenotypes among participants of the Genetics
of Kidney Disease in Zuni Indians study. The study was conducted as a community-
based participatory research project in the Zuni Indians, a small endogamous tribe in rural
New Mexico. We recruited 998 members from 28 extended multigenerational families,
ascertained through probands with CKD who had at least one sibling with CKD. We
used the Illumina Inﬁnium Human1M-Duo version 3.0 BeadChips to type 1.1 million single
nucleotide polymorphisms (SNPs). Prevalence estimates for CKD, hyperuricemia, diabetes,
and hypertension were 24%, 30%, 17% and 34%, respectively. We found a signiﬁcant
(p < 1.58 × 10−7) association for a SNP in a novel gene for serum creatinine (PTPLAD2).We
replicated signiﬁcant associations for genes with serum uric acid (SLC2A9 ), triglyceride
levels (APOA1, BUD13, ZNF259), and total cholesterol (PVRL2).We found novel suggestive
associations (p < 1.58 × 10−6) for SNPs in genes with systolic (OLFML2B), and diastolic
blood pressure (NFIA). We identiﬁed a series of genes associated with CKD and related
cardiometabolic phenotypes among Zuni Indians, a population with a high prevalence of
kidney disease. Illuminating genetic variations that modulate the risk for these disorders
may ultimately provide a basis for novel preventive strategies and therapeutic interventions.
Keywords: single nucleotide polymorphisms, association, kidney function, serum uric acid, triglycerides
INTRODUCTION
The Zuni Indians are experiencing interrelated epidemics of
chronic kidney disease (CKD) and related features of the car-
diometabolic syndrome including obesity, diabetes, dyslipidemia,
and hypertension that are intermediate phenotypes for CKD
(Stidley et al., 2002; Shah et al., 2003; Scavini et al., 2007;MacCluer
et al., 2010). Ethnicity also inﬂuences the risk for the development
of CKD and related phenotypes (Johnson et al., 2009). Genetic
studies, including candidate gene and genome-wide association
studies (GWAS), have been conducted to elucidate the effects of
speciﬁc genes on the variation in CKD and cardiometabolic risk
factors. These include studies conducted in Caucasians (Hwang
et al., 2007; Parsa et al., 2013), African Americans (Edwards et al.,
2008;Willer et al., 2013; Bidulescu et al., 2014),Asians (Yamakawa-
Kobayashi et al., 2012; Willer et al., 2013), Mexican Americans
(Farook et al., 2013; Thameem et al., 2013), Pima Indians (Bian
et al., 2013; Hanson et al., 2013, 2014), and in the 13 Ameri-
can Indian tribes participating in the Strong Heart Family Study
(Franceschini et al., 2013; Voruganti et al., 2014). To decrease the
burden of kidney disease and related intermediate phenotypes in
the Zuni Pueblo, we established the Zuni Kidney Project (ZKP)
in partnership with the Indian Health Service, University of
New Mexico Health Sciences Center, Texas Biomedical Research
Institute and Dialysis Clinic, Inc. (DCI; Stidley et al., 2002).
TheZuni Indians reside in theZuni Pueblo, located inMcKinley
County, NM,USA. The population was 6,302 in the 2010 US Cen-
sus and 97% of inhabitants were American Indians (Zuni Pueblo
Quick Facts). Emigration and immigration rates are lowand there-
fore the population is relatively endogamous. The majority of
adults work as artisans, making jewelry and fetishes. The ZKP
previously conducted a population-based, cross-sectional survey
that reported high prevalence estimates, age-and sex-adjusted to
the Zuni population, for decreased estimated glomerular ﬁltration
rate (eGFR; Scavini et al., 2007), albuminuria (Shah et al., 2003),
and hematuria (Tentori et al., 2003). Prevalence estimates for albu-
minuria and hematuria were higher for diabetic than non-diabetic
participants (Shah et al., 2003). The prevalence of end-stage renal
disease (ESRD) among the Zuni Indians, adjusted for age and
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gender, was 20.0-, 4.4-, and 5.6-fold higher than that among
European– and African–Americans and the composite estimate
for all American Indians (Shah et al., 2003).
Recently the ZKP conducted the Genetics of Kidney Disease in
Zuni Indians (GKDZI) Study to explore the hypothesis that genetic
factors modulate susceptibility to CKD and related phenotypes.
Studies of extended families, such as GKDZI, offer advantages
over studies of sib pairs or unrelated individuals for gene discovery
since they have enhanced statistical power, are more homogenous
and allow for greater genotyping quality control (Laird and Lange,
2008). The current manuscript presents the results of a GWAS in
extended, multigenerational families of Zuni Indians.
MATERIALS AND METHODS
STUDY DESIGN
We conducted a GWAS in extended families of Zuni Indians.
The study cohort consisted of 30 extended families, of which 28
were multigenerational. The families were ascertained through
probands with kidney disease, who had at least one sibling with
kidney disease. The Institutional Review Boards of all participat-
ing institutions and theZuniTribalCouncil approved the protocol.
All participants gave written informed consent.
SETTING
The study was conducted in the Zuni Pueblo. Recruitment
occurred from February 2005 through May 2009. Data were
collected from February 2005 through June 2009.
PARTICIPANTS
We conducted a cross-sectional study of extended families ascer-
tained through probands with CKD who had at least one sibling
with CKD. Potential probands were identiﬁed from the ZKP’s
previous population-based study of kidney disease, which esti-
mated the prevalence of incipient [15%, (13.1–16.9%)] and overt
[4.7% (3.6–5.8%)] albuminuria among 1483 participants (Shah
et al., 2003). Eligibility criteria for probands and affected sib-
lings included age ≥18 years, a urine albumin to creatinine ratio
(UACR) ≥0.2 in at least two of three urine samples or a reduced
serum creatinine-based eGFR, modiﬁed for American Indians
(Shara et al., 2012) using the Chronic Renal Insufﬁciency Cohort
(CRIC) criteria (Feldman et al., 2003). We invited all ﬁrst-degree
(parents, siblings, and offspring), second-degree (aunts, uncles,
nieces, nephews, grandparents, and grandchildren) and third-
degree (ﬁrst cousins, great aunts, great uncles, etc.) relatives of
probands and their spouses over 18 years of age to participate.
See the consort diagram for details of the recruitment process
(Figure 1).We used PEDSYS for data entry, quality control, report
generation, and preparation of data ﬁles for statistical genetic
analysis (Dyke, 1994).
PHENOTYPIC VARIABLES
A random blood sample was drawn from each participant. Blood
was drawn for chemistry proﬁle, hemoglobin A1c (HbA1c), and
serum creatinine and serum uric acid (SUA). We also measured
serum triglycerides, HDL-, LDL-, and total serum cholesterol.
We considered a participant to have diabetes if they met ≥1 of
the following conditions: (1) history of diabetes, (2) random
FIGURE 1 | Study participants, flow diagram.
plasma glucose level ≥200 mg/dL (American Diabetes Associa-
tion, 2012), (3) HbA1c ≥6.5% (American Diabetes Association,
2012), (4) receiving diabetes medication(s). Three urine sam-
ples were collected on separate days from each participant. A
participant was considered to have CKD if UACR ≥0.2 in ≥2
of 3 urine samples or if the eGFR was reduced. We also mea-
sured blood pressure and calculated body mass index (BMI).
Participants were classiﬁed as hypertensive if they met ≥1 of
the following conditions: (1) history of hypertension; (2) SBP or
DBP ≥140 and ≥90mmHg, respectively (73–75), or (3) receiving
antihypertensive medication(s).
GENOTYPIC VARIABLES
DNA samples were obtained from peripheral blood mononu-
clear cells. We conducted genome-wide genotyping for 998
participants using the Illumina Human1M-Duo V3.0 BeadChips
(Illumina, San Diego, CA, USA) that contain ∼1.1 million sin-
gle nucleotide polymorphism (SNP) assays. Illumina included
sample-dependent and independent controls on their chips to test
for accuracy of the procedure. Genotype calls were obtained after
scanning on the Illumina BeadStation 500GX and analysis using
the GenomeStudio software.
GENOTYPING QUALITY CONTROL
Speciﬁc SNPs were removed from analysis if they had call
rates <95% (4,867 SNPs), deviated from Hardy–Weinberg equi-
librium (15), were mono-allelic (136,917) or had rare alleles
occurring in fewer than ﬁve individuals (85,397). SNP geno-
types were checked for Mendelian consistency using the pro-
gram SimWalk (Sobel and Lange, 1996). The estimates of
allele frequencies and their SE were obtained by a maximum
likelihood estimation method that accounts for pedigree struc-
ture using the Sequential Oligogenic Linkage Analysis Routines
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(SOLAR; http://solar.txbiomedgenetics.org), version 4.3 (Almasy
andBlangero,1998), a programpackage that is used for association
analysis, linkage analysis, transmission disequilibrium tests, and
other statistical genetic analyses. Linkage disequilibrium, taking
relatedness into account, was also calculated using SOLAR. Miss-
ing genotypes were imputed from pedigree data using MERLIN
version 1.1.2 (Abecasis et al., 2002).
REDUCING BIAS IN BIOLOGICAL SAMPLES
Reducing bias in UACR
To minimize classiﬁcation bias, we obtained three urine samples
from each participant. The median interval between urine collec-
tions was 2 days. We classiﬁed albuminuria and hematuria using
the mode of three urine samples. UACR was classiﬁed as normal
(<0.03), incipient (0.03–0.19), or overt (≥0.20). If all three sam-
ples were discordant, we used the median value. Urine albumin
was measured using nephelometry (Liu et al., 2011; Nicol et al.,
2011).
Reducing bias in eGFR
We used the four-variable Modiﬁcation of Diet in Renal Disease
(MDRD) Study equation, modiﬁed for use in American Indians
to estimate GFR based on a single serum sample (Shah et al.,
2003; Scavini et al., 2007). Limitations of this equation include
limited validation data in American Indians and the lack of cali-
bration of the serum creatinine assay. Serum creatinine levels are
inﬂuenced by muscle mass. We recognize that the CKD-EPI equa-
tion may out-perform the MDRD equation among people with
near normal kidney function (Levey et al., 2009). Unfortunately,
however, there are few data on the performance of the CKD-EPI
equation among American Indians. We categorized eGFR using
the National Kidney Foundation’s (2002) Kidney Disease Out-
comes Quality Initiative (KDOQI; K/DOQI guidelines) and the
CRIC age-speciﬁc criteria (Feldman et al., 2003). Hyperuricemia
was deﬁned as SUA >6 mg/dl in women and SUA >7 mg/dl
in men.
Genome-wide association analysis (GWA analysis)
Measured genotype analyses were performed using SOLAR ver-
sion 4.3 (Almasy and Blangero, 1998). The number of SNPs
included in the GWA analysis was 884,161. All phenotypes were
transformed by inverse normalization to meet assumptions of
normality. We obtained residuals using linear regression mod-
els adjusted for age, sex, their interactions and higher order
terms. Our subjects were ascertained for CKD. To adjust for ascer-
tainment bias, we took a conservative approach by computing
likelihood for pedigrees incorporating the CKD phenotype as
an additional covariate for kidney function phenotypes (eGFR,
UACR, and serum creatinine; Farook et al., 2012). Additional
covariates included hypertension and diabetic status. Individuals
excluded from analysis included those taking diabetesmedications
for analysis of HbA1c, antihypertensivemedications for analysis of
SBP and DBP, and statins for analysis of lipid traits (triglycerides,
total-, HDL-, and LDL-cholesterol).
Each SNP genotype was converted in MERLIN version 1.1.2
(Abecasis et al., 2002) to a covariate measure equal to 0, 1, or 2
copies of the minor allele (or, for missing genotypes, the weighted
covariate based on imputation). These covariates were included in
the variance-components mixed models for measured genotype
analyses (Boerwinkle et al., 1986) versus null models that incor-
porated the random effect of kinship and ﬁxed effects such as
age, sex, their interaction and higher order terms. For the initial
GWA screen, we tested each SNP covariate independently as a one
degree of freedom likelihood ratio test. An adjusted alpha value
for signiﬁcance, using aMoskvina–Schmidt calculation (Moskvina
and Schmidt, 2008) based on the effective number of independent
SNPs given LD (n = 323,965 SNPs) in the Zuni families, provided
the adjusted genome-wide signiﬁcant and genome-wide suggestive
thresholds of 1.58 × 10−7 and 1.58 × 10−6, respectively. We per-
formed the quantitative transmission disequilibrium test (QTDT)
to test for population stratiﬁcation (Havill et al., 2005). The power
calculations were implemented in SOLAR 4.3.
RESULTS
STUDY PARTICIPANTS
The descriptive characteristics of the GKDZI participants for the
variables included in the GWAS are presented in Table 1. The
mean age was 37.1 ± 13.6 years and 52% were males. Nearly
19% of the participants were diabetic, 34% were hypertensive,
30% had hyperuricemia, and 24% had CKD at the time of the
GKDZI clinic exam. The GWAS included 998 individuals with
available DNA samples. Genotype distributions of all signiﬁcantly
associated SNPs conformed to the Hardy–Weinberg equilibrium.
Population stratiﬁcation was not signiﬁcant as per the QTDT and
therefore did not confound our associations.
GENOME-WIDE ASSOCIATION ANALYSIS
Kidney traits
A genome-wide signiﬁcant association was identiﬁed for serum
creatinine (Table 2). An intronic variant (minor allele G) in
the protein tyrosine phosphatase-like A domain containing 2
(PTPLAD2) gene on Chromosome 9 was signiﬁcantly associated
(p = 1.2 × 10−7) with increased serum creatinine concentra-
tions, with an effect size (residual phenotypic variance that is
contributed by the minor allele of the SNP) of 3.0%. Evidence
of suggestive association was found for serum creatinine with
phospholipase A2 group 4a (PLA2G4A), ATPase, Class V, type
10B (ATP10B), and disks, large homolog 2 (Drosophila; DLG2;
Table 2). However, we did not ﬁnd any signiﬁcant or sugges-
tive associations for eGFR or the urine to albumin creatinine
ratio (UACR). In addition, we found signiﬁcant associations of
SUA with several SNPs in solute carrier family 2, member 9
(SLC2A9) gene (rs6449213, rs938555, rs16890979, rs12499857,
rs734553, rs6832439, rs13125646, rs13131257, rs13145758, and
rs9998811; Figure 2). Minor alleles of most of these SNPs
(shown in detail in Table 3) were associated with lower SUA
levels.
Lipid phenotypes
We analyzed the levels of four lipid phenotypes, e.g., triglyc-
erides, high-density lipoprotein (HDL) cholesterol, low-density
lipoprotein (LDL) cholesterol, and total cholesterol in the GWAS.
The strongest association was found for triglycerides for SNPs
near the zinc ﬁnger protein 259 (ZNF259), apolipoprotein A-1
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Table 1 | Characteristics of traits related to kidney disease, diabetes, and CVD in GKDZI participants.
Phenotypes Trait N % or mean (CI)* Range
Age Age (years) 1000** 37.1 (36.3, 38.0) 18.0–93.1
Sex Men (%) 1000 51.8%
Obesity BMI (kg/m2) 1000 29.6 (29.1, 30.0) 16.8–64.7
Diabetes HbA1c 1000 5.8 (5.7, 5.9) 3.8–14.0
Diabetes (%) 999 18.5%
Serum Lipids Total cholesterol (mg/dL) 992 181.3 (179.2, 183.9) 71.0–400
HDL-C (mg/dL) 947 50.2 (49.1, 51.2) 17.0–131.0
LDL-C (mg/dL) 814 98.8 (96.7, 100.9) 17.0–323.0
Triglycerides (mg/dL) 992 169.0 (161.1, 176.8) 11.0–2000.0
Blood Pressure SBP (mm Hg) 1000 122.4 (121.4, 123.4) 81.3–198.7
DBP (mm Hg) 1000 77.6 (76.9, 78.3) 47.3–132.0
Hypertensive (%) 1000 33.5%
Kidney Function Kidney disease (%) 1000 23.5%
Dialysis (%) 1000 1.2%
Kidney transplant (%) 1000 0.1%
Serum albumin 998 4.29 (4.26, 4.32) 2.0–5.5
Urine albumin 985 12.7 (9.3, 16.1) 0.08–613.0
Serum cystatin C 915 0.86 (0.82, 0.90) 0.44–7.89
eGFRMDRD−AI 998 115.4 (113.5, 117.2) 4.3–249.3
Serum creatinine (mg/dL) 999 0.90 (0.85, 0.95) 0.3–11.2
Urine creatinine 985 130.1 (125.0, 135.2) 3.0–460.5
UACR 985 112.7 (80.2, 145.2) 1.0–9378.5
*Conﬁdence interval.
**Total number of participants in GKDZI study was 1000 of which two were not included in the genome-wide association studies (GWAS).
BMI, body mass index; HbA1c, glycosylated hemoglobin; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; SBP, systolic blood
pressure; DBP, diastolic blood pressure; eGFRMDRD−AI, glomerular ﬁltration rate estimated according to the Modiﬁcation of Diet and Renal Disease modiﬁed for
American Indians; UACR, urine albumin to creatinine ratio Diabetes, any one of the following: (1) history of diabetes; (2) random plasma glucose ≥200 mg/dL;
(3) HbA1c >7.0%; (4) taking diabetes medication(s).
Hypertensive = (1) history of hypertension; (2) SBP >140 mm Hg, and/or DBP >90 mm Hg; (3) currently taking antihypertensive medications.
Kidney disease = (1) UACR >0.03 in two of three spot urine samples; (2) eGFRMDRD−AI <70; (3) renal replacement therapy.
(APOA1), and BUD13 homolog (BUD13) genes on Chromo-
some 11 (Table 4). Triglycerides were signiﬁcantly associated
(p = 1.83 × 10−11 to 6.00 × 10−8) with four SNPs near genes
and one intronic SNP in BUD13 whose mean effect size ranged
from 3.2 to 4.4% (Table 4). All minor alleles of SNPs (effect
sizes ranging between 2.3 and 4.8%) except rs180360 (effect
size = 4.9%) were associated with increased triglycerides. Two
of the SNPs near BUD13 (rs10466588, rs6589563) were in com-
plete LD. Two associated SNPs near the APOA1 gene were also
in complete LD. The mean effect size for the two SNPs was
3.6%. Figure 3 provides a Manhattan Plot for the results of the
genome-wide association analysis with triglyceride levels. The
minor allele (C) of an intronic SNP (rs3852861) in the poliovirus
receptor-related 2 (PVRL2) gene on Chromosome 19 was sig-
niﬁcantly associated (p = 6.44 × 10−8) with increased total
cholesterol. The mean effect size was 3.4% (Table 4). We also
found evidence of suggestive associations for triglycerides, HDL-,
LDL-, and total cholesterol on Chromosomes 17, 16, 2, and 2,
respectively.
Blood pressure
Although GWA analysis of systolic (SBP) and diastolic blood
pressure (DBP) yielded no signiﬁcant associations, several exhib-
ited evidence of suggestive associations (Data not shown). There
were associations with two SNPs near the olfactomedin-like 2B
(OLFML2B) gene on Chromosome 1 that approached signiﬁcance
(p= 9.68× 10−7). The average effect sizewas 3.6%andwas associ-
ated with increases in SBP. There was one intronic SNP in nuclear
factor I/A (NFIA) on Chromosome 1 that showed evidence of
suggestive association (p = 1.23 × 10−6) with decreased DBP.
DISCUSSION
The most signiﬁcant ﬁndings of the ﬁrst GWAS in Zuni Indians
were the strong associations of PTPLAD2, SLC2A9, PVRL2, and
BUD13 with serum levels of creatinine, uric acid, total cholesterol
and triglycerides, respectively. Although, GWA analysis of BMI,
SBP, DBP, and HbA1c provided no signiﬁcant associations, some
traits approached signiﬁcance and several exhibited evidence of
suggestive association.
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FIGURE 2 | Genome-wide association of serum uric acid (SUA) levels.
Manhattan Plot for the results of the genome wide association analysis with
SUA levels. The genome-wide distribution of p-values for each of the SUA
associated single nucleotide polymorphisms (SNPs) is shown. The adjusted
genome-wide signiﬁcant and genome-wide suggestive thresholds were set
at 1.58 × 10−7 and 1.58 × 10−6, respectively. The x axis represents the
genomic position of SLC2A9 SNPs; the y axis shows the −log10 p-value.
There were signiﬁcant associations with 10 SLC2A9 SNPs (rs6449213,
rs938555, rs16890979, rs12499857, rs734553, rs6832439, rs13125646,
rs13131257, rs13145758, and rs9998811).
Table 3 | Significant associations and genotype-specific means of serum uric acid (SUA) levels* (mg/dl).
SLC2A9 SNP Minor
allele/frequency
p-value Effect sizea A/Ac A/Gc G/Gc
rs6449213 G/0.32 4.5 × 10−8b 4.1 6.14 (1.6) 5.80 (1.6) 5.21 (1.5)
rs16890979 G/0.49 6.4 × 10−8 3.7 5.53 (1.6) 5.90 (1.6) 6.22 (1.6)
rs938555 G/0.49 6.6 × 10−8 3.7 5.53 (1.6) 5.89 (1.6) 6.22 (1.6)
rs12499857 G/0.37 8.4 × 10−8 4.3 6.15 (1.6) 5.88 (1.6) 5.23 (1.5)
rs6832439 G/0.49 8.5 × 10−8 3.6 5.53 (1.6) 5.89 (1.6) 6.22 (1.6)
rs734553 A/0.49 8.5 × 10−8 3.6 6.24 (1.6) 5.88 (1.6) 5.56 (1.6)
rs13125646 G/0.49 1.1 × 10−7 3.5 5.56 (1.6) 5.88 (1.6) 6.24 (1.6)
rs13131257 G/0.49 1.1 × 10−7 3.5 5.56 (1.6) 5.88 (1.6) 6.24 (1.6)
rs13145758 A/0.49 1.1 × 10−7 3.5 6.24 (1.6) 5.88 (1.6) 5.56 (1.6)
rs9998811 G/0/49 1.1 × 10−7 3.5 5.56 (1.6) 5.88 (1.6) 6.24 (1.6)
rs7680126 G/0.49 1.3 × 10−7 3.5 6.21 (1.6) 5.88 (1.7) 5.54 (1.6)
rs881971 A/0.48 1.4 × 10−7 3.6 6.22 (1.6) 5.92 (1.6) 5.53 (1.6)
rs13111638 A/0.32 1.5 × 10−7 3.8 5.22 (1.5) 5.80 (1.6) 6.13 (1.6)
∗number of samples included in GWAS analysis = 993.
aProportion of residual phenotypic variance accounted by the minor allele of the single nucleotide polymorphism (SNP).
bGenome-wide signiﬁcance level was set at p < 1.58 × 10−7.
cMean (SD).
We identiﬁed a novel signiﬁcant association of an intronic vari-
ant in the PTPLAD2 gene on Chromosome 9 with an increased
serum creatinine concentration. This gene is part of very long
chain fatty acid dehydratase HACD family and has a key role in
the dehydration step of the very long chain fatty acid metabolism
(Ikeda et al., 2008). Also implicated in tumor suppression (Zuni
Pueblo QuickFacts from the US Census Bureau, 2014), this gene
has not been previously reported to be associated with serum
creatinine. We also found association, albeit suggestive, between
serum creatinine and PLA2G4A, ATP10B, and DLG2 SNPs. Their
role in kidney function is not clear, except that in the kidney,
cytosolic phospholipase A2 seems to play a role in GFR, vascular
tone and water transport (Downey et al., 2001).
The strong association between SUA levels and SLC2A9 SNPs
is a replication and conﬁrmation of these associations in several
populations. Most of these studies were conducted in European
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FIGURE 3 | Genome-wide association analysis of serum triglycerides.
Manhattan Plot for the results of the genome wide association analysis with
serum triglyceride levels. The genome-wide distribution of p-values for each
of the serum triglyceride associated SNPs is shown. The adjusted
genome-wide signiﬁcant and genome-wide suggestive thresholds were set
at 1.58 × 10−7 and 1.58 × 10−6, respectively. The x axis represents the
genomic position of the triglyceride associated SNPs; the y axis shows the
−log10 p-value. The strongest association was for SNPs near the zinc ﬁnger
protein 259 (ZNF259), apolipoprotein A-1 (APOA1), and BUD 13 homolog
(BUD13) genes on Chromosome 11.
populations (Doring et al., 2008; Li et al., 2008; Vitart et al., 2008)
as well as in Asian (Tabara et al., 2010; Guan et al., 2011), African
American (Dehghan et al., 2008; Rule et al., 2011; Tin et al., 2011)
and Mexican American populations (Voruganti et al., 2013). The
effect sizes or the proportion of residual variance in a phenotype
that is explained by theminor allele of the SNP ranged between 3.5
and 4.3% in this study which is similar to what has been reported
by these studies. Similar results were found in a candidate gene
study in American Indians where only seven SLC2A9 SNPs were
genotyped (Voruganti et al., 2014). In addition, Caulﬁeld et al.
(2008) not only conﬁrmed this association in six different cohorts
of European ancestry but showed that SLC2A9 can exchange glu-
cose for urate in the process of secretion of urate into the urine in
functional studies.
Hyperuricemia is associated with hypertension (Johnson et al.,
2005), CKD (Kim et al., 2014), insulin resistance (Cirillo et al.,
2006), and cardiovascular disease (Puddu et al., 2012), although
causality has not been established. SLC2A9 was originally iden-
tiﬁed as glucose transporter 9 (GLUT9). However, it facilitates
electrogenic transport of both hexoses and uric acid in the proxi-
mal tubule (Witkowska et al., 2012). There are two forms, SLC2A9a
and SLC2A9b, which are expressed in the basolateral and apical
membranes of the proximal tubule, respectively. Their amino acid
sequences are identical, except that SLC2A9b has a shorter and
modiﬁed N-terminus. Both forms are active in urate transport in
the proximal tubule (Kimura et al., 2014). Kidney function and
SUA are interrelated (Kang et al., 2002). The anti-hypertensive
drug losartan lowers SUA (Burnier et al., 1996; Wurzner et al.,
2001; Hamada et al., 2002) and confers long-term protection
of kidney function (Brenner et al., 2001). A recent GWAS con-
ducted in Mexican Americans, reported a nominal association
between UACR and SLC2A9 SNPs (Voruganti et al., 2013). We
found nominal associations between SLC2A9 SNPs and kidney
function phenotypes (Data not shown). Our results related to
kidney function phenotypes replicate results of studies conducted
in Mexican Americans and other American Indian tribes (Voru-
ganti et al., 2013,2014). However, our study is different fromothers
as the participating individuals in our study were ascertained
for CKD.
Total serum cholesterol was signiﬁcantly associated with an
intronic SNP (rs3852861) in the PVRL2 gene on Chromosome
19. PVRL2 is located 17 kb downstream from the apolipopro-
tein E (APOE) gene and has also been associated with sever-
ity of multiple sclerosis (Evangelou et al., 1999; Schmidt et al.,
2002), late-onset Alzheimer’s disease (Corder et al., 1993), and
peripheral T-cell lymphomas (Liestol et al., 2000). A study of
Caucasian patients with coronary artery disease found a relation-
ship between homozygosity of the A allele in a polymorphism
of the PVRL2/PRR2 gene and premature cardiovascular disease
(Freitas et al., 2002). The authors suggested that this ﬁnding could
be related to viral association or linkage disequilibrium between
PRR2 and nearby (17 kb centromeric) apolipoprotein E (APOE;
Willer et al., 2008). This gene was also associated with LDL choles-
terol in a Caucasian population although the chromosomal region
is not the same (Talmud et al., 2009). We also found evidence
of suggestive association of cholesterol esterase transfer protein
(CETP) with HDL cholesterol which is a replication of several
studies (Feitosa et al., 2014; Singaraja et al., 2014; Walia et al.,
2014).
The association of triglycerides with four SNPs near and one
SNP in the BUD13/ZNF259 region replicates results observed in a
Mexican cohort (Weissglas-Volkov et al., 2010), a meta-analysis
of individuals of European descent (Schunkert et al., 2011), a
Finnish cohort (Kristiansson et al.,2012) andAsian Indians (Braun
et al., 2012). The minor allele frequency for rs964184 is higher
among Zuni Indians (39%) than among Mexicans (27%), Asian
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Indians (15%) or Whites (12%). The ZNF259/BUD13 associa-
tions with triglyceride levels have been reported in GWAS in
the Framingham Study (Suchindran et al., 2010), which also
showed an association with lipoprotein-associated phospholipase
A2 (Lp-PLA2), a risk factor and possible therapeutic locus for
CVD. Similarly, ZNF259 was signiﬁcantly associated with Lp-
PLA2 activity in a meta-analysis of ﬁve population-based studies
(Grallert et al., 2012). ZNF259 codes for ZPR1, a zinc (as well
as some other metals) binding protein, which may play a role
in signal transfer from cell cytoplasm to the nucleus and cell
proliferation (Galcheva-Gargova et al., 1998). This region of the
ZNF259/BUD13, APOA1/C3/A4/A5 genes has also been associated
with coronary artery disease (Waterworth et al., 2010).
In addition, we also found some novel, albeit suggestive,
associations of various SNPs with cardiometabolic phenotypes
such as SNPs near OLFML2B and NOS1AP with blood pres-
sure phenotypes. Although these SNPs have not been associated
with blood pressure before, they have been associated with the
Short QT-Syndrome among individuals from the UK and North
America (Eijgelsheim et al., 2009; Nolte et al., 2009). Similarly,
variants in the NFIA gene, which encodes the nuclear factor 1
family of transcription factors have been associated with QRS
duration in individuals of European descent (Sotoodehnia et al.,
2010).
STRENGTHS AND LIMITATIONS
The strengths of our study include a dense GWAS using an Illu-
mina chip that was state of the art at the time the study was
conducted. Conducting the study in extended families from a rela-
tively endogamous population increased our statistical power and
minimized potential population stratiﬁcation. Furthermore, we
utilized state of the art programs for conducting genetic analy-
ses (SOLAR, MERLIN). All study staff members working in Zuni
were Zuni, which enhanced community acceptance of performing
genetic studies in the Pueblo. Our study also had some signiﬁcant
limitations. We did not perform direct measurements of GFR.
The serum creatinine assay was performed in a clinical laboratory
and not standardized. The GFR estimating equation has not been
validated in Zuni Indians. Kidney biopsies were not performed
and may have led to misclassiﬁcation. We did not account for
all possible genetic X environmental interactions. In addition, we
did not have positive controls. However, several of our signiﬁcant
loci have been previously identiﬁed in individuals without kidney
disease.
CONCLUSION
The results of the GKDZI study support our hypothesis that
genetic factors signiﬁcantly inﬂuence susceptibility to CKD and
related cardiometabolic phenotypes among Zuni Indians.
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